Chakravarty Geetika, Santillan Alfredo A, Galer Chad, Adams Henry P, El-Naggar Abdal K, Jasser Samar A, Mohsin Sayed, Mondal Debasis, Clayman Gary L, Myers Jeffrey N
Department of Pharmacology, Tulane University Health Science Center, School of Medicine, New Orleans, LA 70112, USA.
Exp Biol Med (Maywood). 2009 Apr;234(4):372-86. doi: 10.3181/0809-RM-284. Epub 2009 Jan 28.
Overexpression of insulin-like growth factor-I receptor (IGF-IR) is seen in a multitude of human thyroid cancers and correlates with poor prognosis. However, recent studies suggest that low phospho-IGF-IR (pIGF-IR) expression rather than its overexpression may be an indicator of poorly differentiated disease. No previous study has evaluated the expression of pIGF-IR to determine if activation or loss of expression of this receptor is associated with thyroid tumor progression. Accordingly, a quantitative immunohistochemical (IHC) method was used to evaluate the clinico-pathological significance of pIGF-IR expression in archival samples of human thyroid carcinomas. Quantitative analysis of pIGF-IR levels revealed a significant difference in the median index of pIGF-IR between different histological subtypes of thyroid cancer (P < 0.001). Specifically, the median pIGF-IR index of differentiated thyroid cancers was significantly higher than the median index of other poorly differentiated thyroid cancer (P < 0.001). This was further confirmed in individual tumor sections of thyroid carcinoma where anaplastic and differentiated components co-existed. No significant difference was noted in the pIGF-IR index of tumors grouped by size or stage but a trend towards lower mean pIGF-IR index was noted in older patients. Our data indicates that pIGF-IR is upregulated in a majority of follicular thyroid carcinomas, suggesting it may be a potential target for therapy for patients with this disease. In addition, since low pIGF-IR expression was found to correlate with aggressive human thyroid carcinoma, it also suggests that IGF-IR may not be needed for progression of anaplastic thyroid carcinoma possibly because other cell signaling pathways are activated, obviating the need for IGF-IR signaling. However, more mechanistic studies would be necessary to substantiate the possibility that pIGF-IR may be important for differentiation of thyroid tissues and is lost with disease progression.
胰岛素样生长因子-I受体(IGF-IR)在多种人类甲状腺癌中呈过表达,且与预后不良相关。然而,最近的研究表明,低磷酸化IGF-IR(pIGF-IR)表达而非其过表达可能是疾病分化不良的一个指标。此前尚无研究评估pIGF-IR的表达,以确定该受体的激活或表达缺失是否与甲状腺肿瘤进展相关。因此,采用定量免疫组织化学(IHC)方法评估pIGF-IR表达在人类甲状腺癌存档样本中的临床病理意义。pIGF-IR水平的定量分析显示,甲状腺癌不同组织学亚型之间pIGF-IR的中位指数存在显著差异(P < 0.001)。具体而言,分化型甲状腺癌的pIGF-IR中位指数显著高于其他低分化甲状腺癌的中位指数(P < 0.001)。在间变性和分化成分共存的甲状腺癌单个肿瘤切片中,这一点得到了进一步证实。按大小或分期分组的肿瘤的pIGF-IR指数未观察到显著差异,但老年患者的平均pIGF-IR指数有降低趋势。我们的数据表明,大多数滤泡性甲状腺癌中pIGF-IR上调,提示它可能是该疾病患者的潜在治疗靶点。此外,由于发现低pIGF-IR表达与侵袭性人类甲状腺癌相关,这也表明间变性甲状腺癌的进展可能不需要IGF-IR,可能是因为其他细胞信号通路被激活,从而无需IGF-IR信号传导。然而,需要更多的机制研究来证实pIGF-IR可能对甲状腺组织分化很重要且会随着疾病进展而丧失这一可能性。